Certara, Inc. · NASDAQ:CERT
Certara — Technical Presentation (2014)
29 slides from Certara's technical presentation, 2014
Slide 1: Pediatric PBPK: Developing the models
Pediatric PBPK: Developing the models Refining the System Parameters Dr Trevor Johnson Principal Scientist Simcyp Limited trevor.johnson@certara.com
Slide 2: Pediatric-PBPK model building
Pediatric-PBPK model building © Copyright 2014 Certara, L.P. All rights reserved. 2
Slide 3: Separating Systems & Drug Information
Separating Systems & Drug Information Systems Drug Trial Data Data Design Age MW Weight Dose LogP Tissue Volumes Route pKa Tissue Composition Frequency Protein binding Cardiac Output Co-administered drugs BP ratio Renal elimination Populations studied In vitro Plasma Protein Metabolism Enzymes Perme
Slide 4: Systems data: The Complexity of Covariate Effects
Systems data: The Complexity of Covariate Effects Genotypes (Distribution in Population) Renal Function Plasma Body Ethnicity Disease Proteins Fat Serum & Creatinine Haematocrit Sex Age (Distribution in Population) (Distribution in Population) Height Brain Body Volume Heart Surface Volume Area Weigh
Slide 5: Linking the Current Models to Paediatric Models
Linking the Current Current Models Paediatric Models Drug Elimination Drug Distribution Lung Lung Population: Population: N Subject N Subject of Known Age/SexAge/Sex of Known Population Population Adipose Adipose Liver: Liver: Specific Specific weight/blood flow weight/blood flow Inputs Inputs Paedi
Slide 6: System parameters in prediction of pediatric drug CL
System parameters in prediction of pediatric drug CL In vitro CLuint per Vmax/Km g Liver or *CLuint Scaling Scaling Scaling CLuint per Factor 1 Factor 2 Factor 3 Liver * Or from in vivo retrograde model CYP Abundance UGT Abundance MPPGL Ontogeny Liver Weight Liver blood flow CLH = QH.fuB.CLuint QH +
Slide 7: Liver Volume: Changes with Age
Liver Volume: Changes with Age Liver Volume = 0.722 * BSA1.176 Analysis based on 5036 subjects 2.5 Simcyp Liver Volume (L) 2 In vivo 1.5 Adult 1 0.5 0 0 5 10 15 20 25 30 Age (y) © Copyright 2014 Certara, L.P. All rights reserved. 7
Slide 8: Maturation of Renal Clearance
Maturation of Renal Clearance 150 Johnson et al 2006 GFR (ml/min) 100 921 subjects 923 subjects 50 y = 87.674x - 14.497 R 2 = 0.9988 0 0 0.5 1 1.5 2 1760 subjects BSA (m2) 63 subjects 160 Rhodin et al 2009 140 140 Johnson et al 2006 De Cock Rhodin, De Cock , Hayton (ml/min) De Cock et al 2014 120 Rh
Slide 9: CYP Ontogeny
CYP Ontogeny Johnson 2006 Updated 2009 1.2 CYP1A2 1.2 1.2 CYP2B6 CYP2C8 1 1 1 0.8 0.8 0.8 0.6 0.6 0.6 0.4 0.4 Croom et al 2009 0.4 0.2 0.2 0.2 0 0 0 0 5 10 15 20 0 5 10 15 20 0 5 10 15 20 1.2 1.2 CYP2C19 1.2 CYP2C9 CYP2D6 1 1 1 Fraction 0.8 0.8 0.8 0.6 0.6 0.6 Stevens et al 2008 0.4 0.4 Hines 2007 0
Slide 10: How certain are we about ontogeny?
How certain are we about ontogeny ? © Copyright 2014 Certara, L.P. All rights reserved. 10
Slide 11: Potential problems in determining CYP ontogeny
Potential problems in determining CYP ontogeny • Does in vitro relate well to in vivo? (co-factors, endogenous substrates, hormones) • Genotype - phenotype relationships • Lack of information and lumping of age bands • Availability and handling of clinical samples – Ethics – Drug and nutritional his
Slide 12: CYP2D6 - Bottom-Up Approach Meets Top-Down
CYP2D6 - Bottom-Up Approach Meets Top-Down Clin Pharmacol Ther 2007 Clin Pharmacol Ther 2008 (A) 1 1 (B) CYP3A4 activity (DX/3HM CYP2D6 activity (DM/DX ratio) relative to adult ratio relative to adult 0.8 0.8 0.6 0.6 0.4 0.4 0.2 0.2 0 0 0 4 8 12 0 4 8 12 Age (Months) Age (Months) Figure 1. Changes i
Slide 13: UGT2B7 - Bottom up meets Top down again
UGT2B7- Bottom up meets Top down again (but not every time!!) Top down Clearance (L/h) Clearance (L/h) Bodyweight (kg) Bodyweight (kg) Bottom up • Take home message is that pattern of ontogeny appears to be reasonable except for early neonates • But under-prediction of CL across age band with morphi
Slide 14: p-PBPK prediction accuracy
p-PBPK prediction accuracy Leong et al CPT 2012 Overall picture is one of under-prediction with possible reasons −Ontogeny profile incorrect −Other pediatric physiology incorrect - LW, LBF and fu - robust data −Clinical studies not representative / misinterpreted? © Copyright 2014 Certara, L.P. All
Slide 15: Shifting the focus: Systems-focused modelling
Shifting the focus: “Systems-focused” modelling © Copyright 2014 Certara, L.P. All rights reserved. 15
Slide 16: Clinical data: Decompose to rebuild
Clinical data: Decompose to rebuild Taking away the • Protein Binding • Red Cell Partitioning known effects of: • Renal Elimination • Liver Size • Liver blood flow • Renal clearance © Copyright 2014 Certara, L.P. All rights reserved. 16
Slide 17: Revised CYP3A ontogeny based on in vivo data
Revised CYP3A ontogeny based on in vivo data Midazolam iv data 1* PMA3.9 CYP3A4 = 3.9 71 + PMA3.9 1.2 CYP3A ontogeny 1 Relative expression 0.8 0.6 Latest in vivo Correct for effects of ventilation and disease In vitro ontogeny 0.4 0.2 0 0 5 10 15 20 Age (y) © Copyright 2014 Certara, L.P. All rights
Slide 18: Revised CYP1A2 ontogeny based on in vivo data
Revised CYP1A2 ontogeny based on in vivo data Caffeine and theophylline data 1.6 * PMA 5.7 CYP1A2 = 54.6 5.7 + PMA 5.7 CYP1A2 = 0.8 * exp −0.001*(PMA−196) + 0.8 1.8 1.6 CYP1A2 ontogeny 1.4 Relative expression 1.2 1 in vivo ontogeny 0.8 in vitro ontogeny 0.6 0.4 0.2 0 0 5 10 15 20 25 30 Age (y) © Cop
Slide 19: Performance of CYP1A2 and 3A in vivo vs in vitro ontogeny model
Performance of CYP1A2 and 3A in vivo vs in vitro ontogeny model Independent data sets © Copyright 2014 Certara, L.P. All rights reserved. 19
Slide 20: Expansion of in vivo-based ontogeny function: CYP2C9
Expansion of in vivo-based ontogeny function: CYP2C9 • CYP2C9 (ibuprofen) – Patent Ductus Arteriosus – Cystic Fibrosis – Febrile Children In vitro In vivo 1.0 1.E+01 CLint (ul/min/mg of mic) Fraction of adults ratio paed:adult 1.E+00 1.E-01 1.E-02 0.1 1.E-03 0 5 10 15 20 -10 0 10 20 30 40 Age (years
Slide 21: Expansion of in vivo-based ontogeny functions: 2C19
Expansion of in vivo-based ontogeny functions: 2C19 • CYP2C19 (pantoprazole) – GERD 1.0 10.0 CLint (ul/min/mg of mic) In vitro In vivo Fraction of adults ratio paed:adult 1.0 0.1 0.1 0 5 10 15 20 25 -10 0 10 20 30 40 Age (years) Age (years) • In vivo-based CYP2C19 function requires to be validated w
Slide 22: Relative Importance of Pathways: Ratio of Ratios
Relative Importance of Pathways: “Ratio of Ratios”! Pathway A in Pediatrics Pathway A in Adults J Clin Pharmacol 2013; 53: 857–865 Relative Ontogeny = Pathway B in Pediatrics Pathway B in Adults X vs CYP2C9 Ratio X(adult/Paed):CYP29 (Adults/Paed) 3.00 Renal 2.00 1.00 CYP2C8 0.60 CYP2E1 0.50 0.40 CYP
Slide 23: Evaluating and using p-PBPK models
Evaluating and using p-PBPK models If compound does not work in adult PBPK model – STOP! © Copyright 2014 Certara, L.P. All rights reserved. 23
Slide 24: The current reality: The learn and confirm approach
The current reality: The learn and confirm approach Healthy volunteer Pediatric Lung Lung Additional Additional Organ Organ Adipose Adipose Bone Bone Brain Brain Arterial Blood Venous Blood Arterial Blood Venous Blood Heart Heart Kidney Kidney Muscle Muscle Skin Skin Liver Liver Spleen Spleen Portal
Slide 25: Learn and confirm: p-PBPK examples
Learn and confirm: p-PBPK examples Biopharm Drug Dispos 2014 online. Clin Pharmacokinet, 2014; 53, 89-102. © Copyright 2014 Certara, L.P. All rights reserved. 25
Slide 26: Evaluating p-PBPK: Care in selection of clinical studies
Evaluating p-PBPK Care in selection of clinical studies Trial Clearance Totals for 50 Groups of 2 Individuals out of a Population of 100 1. N = 2 Oral omeprazole 1.20 5 Clinical data range Mean Andersson 2000 4.5 Geo mean Andersson 2000 2. Substrate file not predicting properly 1.00 1 - <6y 0.49 toi
Slide 27: The ultimate goal
The ultimate goal • More than one way of using pediatric PBPKs to better understand the system. • Learn and confirm approach often used. • Compare like with like if comparing models e.g. same / similar input parameters. • Ultimate goal is to move to right © Copyright 2014 Certara, L.P. All rights re
Slide 28: Conclusions
Conclusions • Pediatric PBPK models have the potential to improve drug development. − Especially under ~2 years − But over 2 years for DDI / Complex PK / Bridging formulations • Pediatric PBPK models still evolving and some system parameters are known unknowns. − Transporter ontogeny − Intestinal UG
Slide 29: Acknowledgements
Acknowledgements • Prof Amin Rostami-Hodjegan • Prof Geoff Tucker • Dr Khaled Abduljalil • Dr Farzaneh Salem • Dr Goahua Lu • Dr Alice Ke • Mr Felix Stader © Copyright 2014 Certara, L.P. All rights reserved. 29